Canadian company Aurinia Pharmaceuticals is set to commence clinical trials next year for treatment of renal disorders and keratoconjunctivitis sicca or dry eye syndrome (DES) with its drug candidate, voclosoprin.

Voclosporin is an investigational immunosuppressant being developed to inhibit calcineurin, blocking IL-2 expression and T-cell mediated immune responses, as well as stabilising kidney’s podocyte.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

In the first half of next year, the firm will start a Phase II trial for focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD).

The firm is planning for a Phase IIa trial of voclosporin ophthalmic solution (VOS) in the second quarter to treat DES.

Interim data from Phase II and results from the Phase IIa trial are scheduled to be available in the second half.

“We hope to bring new treatment options to patients where significant unmet medical need remains.”

Furthermore, Aurinia anticipates that the ongoing Phase III clinical trial (AURORA), which has 113 active trial sites for the treatment of lupus nephritis (LN), will complete enrolment in the second half.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Aurinia Pharmaceuticals chairman and CEO Richard Glickman said: “With the AURORA trial in LN now well underway, we’re poised to enter the next phase of development for Aurinia.

“By leveraging our expertise and the unique profile of voclosporin to pursue these novel indications, we hope to bring new treatment options to patients where significant unmet medical need remains.”

Under the fast drug designation of voclosporin, the firm intends to use a rolling new drug application (NDA) process and is planning for the submission of first module in the second half of next year.